Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Conference call May 9th Folks!!
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update.
The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and asking to be connected to the "Virios Therapeutics Conference Call" using the access code: 739495.
About Virios Therapeutics
Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (“FM”) and Long-COVID (“LC”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndromes, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system. The Company’s lead development candidates are novel, proprietary, fixed dose combinations of an antiviral compound and celecoxib designed to synergistically suppress herpesvirus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 (fixed dosage combination of famciclovir and celecoxib) has been granted fast track designation by the FDA.
For more information, please visit www.virios.com.
Yeah man, and VIRI is definitely a buy and hold in my book.👍
That is how these small bio plays work though. You buy the stock expecting that they get bought out by the giant pharmaceuticals like Pfizer, Merck, etc. Virios could be bought out any day or not. But the more successful they are, the greater the chance (not that that is rocket science)
Hmmm a little action today
I’ll be right here waiting no matter how long it takes.😎
Right with you with those thoughts.
I truly believe it’s going to be worth the wait bud😎💰
Mr. Duncan, while at Pfizer he held several executive U.S. and international appointments, including President of Pfizer’s $2B Latin America Operations and SVP of Marketing. His operational teams had accountability for the launches of many pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent, Rebif and Vimpat.
Great color. I’ll be waiting. Thanks!
I truly believe it’s going to be worth the wait bud😎💰
Mr. Duncan, while at Pfizer he held several executive U.S. and international appointments, including President of Pfizer’s $2B Latin America Operations and SVP of Marketing. His operational teams had accountability for the launches of many pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent, Rebif and Vimpat.
On that note, I added again this am
I believe Greg Duncan Viri CEO mentioned the aim for the first Quarter 2024 to settle a partnership or funding opportunity, let us see if he delivers on time
$VIRI
— Frank_Benedetto (@FrankieBstock) April 17, 2024
They keep on highlighting this..are they foreshadowing or begging? 🤔 https://t.co/xtSKqZwBMF
JAGX average was .07 it crossed .25
Which one? Congratulations
Added .46s to me stash, these bios have a tendency to go ballistic without notice, like what one of mine did today
My Magic 8 Ball says hell yeah!😎💰
$VIRI
— Frank_Benedetto (@FrankieBstock) April 11, 2024
They have been mentioning this repeatedly. Does this hint at a forthcoming deal/opportunity coming? https://t.co/jpJjAoVzxF
Keep bringing the social media posts😎 I have a feeling we’re close to GREATNESS💰
As reported in US News and World Reporthttps://t.co/0q8eMme3FB pic.twitter.com/uKVD3yB8Op
— Virios Therapeutics (@ViriosBiotech) April 11, 2024
This needs to stop bleeding
Added a tad more this am
Missed it but ready for more
Here we go Action
These Bios are quiet until they are not..
Added .46s !!!
VIRI getting pretty active on X😎💰
— Virios Therapeutics (@ViriosBiotech) April 8, 2024
I added .46s...
Fun one is breaking down in failure again. Not my fault.
Clowns making shiate up? Good clowns
That's a nice target.!!
What's happening at 2:45 .. are you referring to power hour?
Very nice
Added more .51s
She is going on o be a beauty!
LMAO
Same thing they said last year from .0042 -$2.45
They don't trade up everyday but when they do oh baby!!!!
This POS better hold more volume and continue the trend or it will always poop back to the toilet level.
This is going to be a fun one…. I want to grab more shares over the next month so hopefully we hang around here. Don’t get me wrong, I’ll take a buyout with my current shares I bought but I want more!
Pretty sure that's why we all bought back in.
Grabbed some shares. I hope these guys get taken out by a big bio pharmaceutical company. That is usually the case with these smaller successful bio cos
Good move bud👍 The VIRI CEO knows plenty of people in the pharmaceutical industry, so hopefully he already has people knocking on his door.
Followers
|
62
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4064
|
Created
|
06/09/21
|
Type
|
Free
|
Moderators DavidLeeRoth |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |